← All trials
NCT05628311
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2022
- Primary completion
- Jan 8, 2024
- Completion date
- Jan 15, 2025
- First posted
- Nov 28, 2022
- Last posted
- Nov 28, 2022
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Innovent Biologics (Suzhou) Co. Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.